Navigation Links
Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from,Human Clinical Trials for New Cancer Drug

PASADENA, Calif.--(BUSINESS WIRE)--Jun 1, 2007 - Arrowhead Research Corporation (Nasdaq:ARWR) announced today that interim Phase I data has been published in the 2007 American Society for Clinical Oncology Proceedings (ASCO) (Abstract ID 32638). The data are from an ongoing Phase I clinical study designed to evaluate the safety, tolerability, and pharmacokinetics of its lead anti-cancer drug candidate, IT-101, in patients with inoperable or metastatic tumors. IT-101 is a conjugate of the potent anti-cancer drug camptothecin and Insert's proprietary drug delivery technology, Cyclosert(TM).

"The interim IT-101 study results look very promising," stated R. Bruce Stewart, Chairman of Arrowhead. "We were encouraged to see patients who have failed other chemotherapies complete the whole six cycles of treatment without disease progression."

The abstract's authors state that the stable disease rate, although not yet conclusive, is consistent with promising efficacy. In general, IT-101 was well tolerated and pancytopenia was the dose limiting toxicity. Patients that have completed the six cycle treatment regimen and showed stable disease or better are expected to continue to receive treatment on a compassionate care basis. The first person to enter the trial, a pancreatic cancer patient, is stable after 10 months.

"The type of dose limiting toxicity identified is consistent with the expectation for a camptothecin derivative," said Dr. Thomas Schluep, Chief Scientific Officer at Insert. "We are encouraged that, at dose levels that have promising efficacy, we have not seen some of the other deleterious side effects commonly experienced by patients receiving camptothecin class drugs."

Pharmacokinetics data were favorable and consistent with results from preclinical animal studies. In the patients studied, IT-101 showed longer half life, lower clearance and lower volume of distribution than seen in pati
'"/>




Page: 1 2 3

Related medicine technology :

1. Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting
2. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
3. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
4. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
5. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
6. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
7. The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
8. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
9. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
10. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
11. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
Post Your Comments:
(Date:4/21/2015)... , April 21, 2015 Cardiologists at Henry ... of stroke in patients with an irregular heartbeat. ... procedure, Henry Ford is able to add another ... atrial fibrillation, which affects the heart,s ability to pump. ... and first-ever commercial Watchman implant at a non-clinical ...
(Date:4/21/2015)... 21, 2015  Celebrating a major anniversary and ... same time is fitting for Enova Illumination. In ... surgical headlights, LED technology was a new concept ... been at the forefront of LED surgical headlight ... lightest and most dependable LED surgical headlights available. ...
(Date:4/21/2015)... , April 21, 2015 Workers, compensation ... 5.4 percent decrease in utilization helped offset a 7 ... new data released today by Express Scripts (NASDAQ: ... Workers, Compensation Drug Trend Report discusses the overall pharmacy ... among injured workers. Opioid Management Mitigates ...
Breaking Medicine Technology:Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 2Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 3Enova Illumination Celebrates 10th Anniversary at Cutting Edge of LED Surgical Headlight Innovation; Introduces Newest and Brightest LED Surgical Headlight in the World 2Enova Illumination Celebrates 10th Anniversary at Cutting Edge of LED Surgical Headlight Innovation; Introduces Newest and Brightest LED Surgical Headlight in the World 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 2Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 4
... WAYNE, N.J., June 6, 2011 Bayer HealthCare Pharmaceuticals ... AL pharadin in SYM ptomatic P rostate ... chloride, which is exclusively licensed from Algeta ASA, in ... met its primary endpoint by significantly improving overall survival. ...
... June 5, 2011 Nektar Therapeutics (Nasdaq: ... of patients in a Phase 2 clinical study evaluating ... total of 33 women in the study with prior ... for response rate using either RECIST 1.0 criteria (response ...
Cached Medicine Technology:Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone 2Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone 3NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 2NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 3NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 4NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 5NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 6NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 7NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 8
(Date:4/21/2015)... Angelo’s FabriClean has recently announced that ... clients that avail the area rug cleaning services. Area ... with hi-tech equipments, making use of the quick drying ... natural, high pressure steam extraction to clean even the ... area rugs made with delicate fabric. , “Good ...
(Date:4/21/2015)... April 21, 2015 Catalent (Booth ... technologies and development solutions for drugs, biologics and ... ADVASEPT™ Lock, a stopper-less, glass- and needle-free vial ... medications. Easily opened, ADVASEPT Lock attaches to a ... container closure with the security of an advanced ...
(Date:4/21/2015)... QuickMedical, a veteran-owned leader in ... represents Schiller America's line of Ambulatory ... and Vital Signs Monitors, among many other items. ... global leader in the development and production of ... close cooperation with the world's leading physicians and ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 The ... Citrate Industry is a professional and in-depth study ... Sodium Citrate Market with a focus on ... in the sodium citrate market research are Cargill, ... Natural Biological, Cofco Biochemical, Capchem, Lianyungang Mupro Fi, ...
(Date:4/21/2015)... April 21, 2015 Further strengthening ties ... $1.2 million in donated goods and services to the ... through the USF Health BRIDGE Healthcare Clinic. , The ... clinic in its eighth year – provides primary medical ... one night a week inside the USF Health Morsani ...
Breaking Medicine News(10 mins):Health News:Angelo’s FabriClean Now Offers Area Rug Cleaning in South Surrey with Complimentary Pick-Up and Delivery 2Health News:Catalent Announces the Expansion of its Advanced, Aseptic, Glass-Free Injectable Platform with New ADVASEPT™ Lock Delivery Technology 2Health News:QuickMedical Launches New Product Line: Schiller America 2Health News:QuickMedical Launches New Product Line: Schiller America 3Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 2Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 3Health News:USF Health and Florida Hospital Tampa Partner to Expand BRIDGE Clinic 2Health News:USF Health and Florida Hospital Tampa Partner to Expand BRIDGE Clinic 3
... 24, 2011David Satcher, MD, PhD, former U.S. Surgeon General, describes ... and adult health that we are facing today," calling for ... in the June issue of Childhood Obesity , a ... is available online. A long-time advocate in the ...
... , FRIDAY, June 24 (HealthDay News) -- Drinking even ... concentrations enough to increase the chances of being seriously injured ... get behind the wheel, a new study suggests. Researchers ... a blood-alcohol concentration of just 0.01 percent -- much lower ...
... June 24, 2011 A new anti-inflammatory drug used by ... a year-long study involving researchers from UT Southwestern Medical Center. ... Journal of Medicine , mark the first time a drug ... type 2 diabetes and chronic kidney disease. Previous studies have ...
... Researchers from Boston University,s Slone Epidemiology Center have found ... (MHC) that confer a higher risk of systemic lupus ... currently appears on-line in Human Genetics , is ... association between genetic variants in the MHC region and ...
... , THURSDAY, June 23 (HealthDay News) -- After suffering a ... and fears about the future are less depressed and live ... In fact, 48 percent of the people who participated in ... were not depressed a year later, compared to 37.7 of ...
... (HealthDay News) -- New research suggests that the adverse effects ... latest findings, from a University of Rhode Island study that ... revealed that preemies grow up to be less healthy, struggle ... compared to those born full-term. One reason for this, ...
Cached Medicine News:Health News:Even One Glass of Beer, Wine Boosts Car Crash Risk: Study 2Health News:Drug shows improved kidney function for type 2 diabetics, UT Southwestern researchers report 2Health News:New genetic risk factors of lupus found in study of African-American women 2Health News:Early Talk Therapy May Help Stroke Patients Bounce Back 2Health News:Early Talk Therapy May Help Stroke Patients Bounce Back 3Health News:Effects of Premature Birth May Stretch Into Adulthood: Study 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: